Physicians from around the United States continue to emerge, going public with their declaration of the benefits of ivermectin as an early onset, mild-to-moderate stage COVID-19 treatment. Most recently on KETV 7 Omaha, Dr. Louis Safranek came forth, declaring, “I typically use it in combination with other agents. But I do prescribe it for virtually all the patients who come to be, as part of a treatment regimen, which I think is effective for folks.” The Harvard Medical School graduate has been specializing in infectious diseases for four decades. Having treated nearly 200 COVID-19 patients at home and in the local hospitals here in Omaha, Nebraska, ivermectin is a key medicine tool in the medicine box targeting COVID-19.

TrialSite can assure that the National Institute of Health (NIH) formal policy in fighting the pandemic is to have a comprehensive mix of 1) safe and effective vaccines, 2) branded therapeutics, 3) generic repurposed therapeutics, and 4) sound and locationally relevant public health policy. Of course, industry bias has reared its ugly head in this pandemic as the NIH and the federal government have spent many billions on vaccines and novel investigational the…

Continue Reading Here

Comments

0 Comments

Submit a Comment